Celsius (NASDAQ:CELH) PT Lowered to $85.00 at Stifel Nicolaus

Celsius (NASDAQ:CELH) had its price objective reduced by stock analysts at Stifel Nicolaus from $95.00 to $85.00 in a report released on Thursday, Benzinga reports. The brokerage presently has a “buy” rating on the stock. Stifel Nicolaus’ price objective would suggest a potential upside of 14.31% from the stock’s current price.

CELH has been the topic of several other reports. Jefferies Financial Group raised their target price on Celsius from $98.00 to $105.00 and gave the company a “buy” rating in a research report on Monday, March 18th. Wedbush boosted their price target on Celsius from $75.00 to $90.00 and gave the stock an “outperform” rating in a research report on Monday, March 4th. UBS Group boosted their price target on Celsius from $73.00 to $99.00 and gave the stock a “buy” rating in a research report on Friday, March 1st. Roth Mkm boosted their price target on Celsius from $90.00 to $105.00 and gave the stock a “buy” rating in a research report on Thursday, March 14th. Finally, Stifel Europe boosted their price target on Celsius from $90.00 to $95.00 and gave the stock a “buy” rating in a research report on Monday, March 18th. Two research analysts have rated the stock with a hold rating and twelve have given a buy rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $84.74.

Celsius Stock Up 2.8 %

CELH stock traded up $2.02 during mid-day trading on Thursday, reaching $74.36. The company had a trading volume of 2,511,975 shares, compared to its average volume of 4,607,505. Celsius has a one year low of $32.99 and a one year high of $99.62. The stock has a market capitalization of $17.18 billion, a P/E ratio of 96.21, a P/E/G ratio of 2.08 and a beta of 1.93. The stock’s 50-day simple moving average is $80.34 and its two-hundred day simple moving average is $65.26.

Celsius (NASDAQ:CELH) last posted its earnings results on Thursday, February 29th. The company reported $0.17 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.16 by $0.01. Celsius had a net margin of 17.21% and a return on equity of 131.58%. The firm had revenue of $347.44 million during the quarter, compared to analyst estimates of $326.77 million. During the same period in the previous year, the business posted $0.01 EPS. Celsius’s revenue was up 95.2% on a year-over-year basis. On average, research analysts forecast that Celsius will post 1.09 EPS for the current fiscal year.

Insider Transactions at Celsius

In other news, major shareholder William H. Milmoe sold 428,568 shares of the company’s stock in a transaction dated Monday, April 29th. The stock was sold at an average price of $59.67, for a total transaction of $25,572,652.56. Following the completion of the sale, the insider now owns 25,464,453 shares in the company, valued at approximately $1,519,463,910.51. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. In other news, Director Caroline S. Levy sold 20,000 shares of the firm’s stock in a transaction on Wednesday, March 13th. The shares were sold at an average price of $94.77, for a total value of $1,895,400.00. Following the sale, the director now owns 37,891 shares in the company, valued at $3,590,930.07. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, major shareholder William H. Milmoe sold 428,568 shares of the firm’s stock in a transaction on Monday, April 29th. The stock was sold at an average price of $59.67, for a total transaction of $25,572,652.56. Following the completion of the sale, the insider now owns 25,464,453 shares in the company, valued at approximately $1,519,463,910.51. The disclosure for this sale can be found here. In the last quarter, insiders sold 1,253,278 shares of company stock worth $83,587,047. 2.20% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Celsius

Several hedge funds and other institutional investors have recently modified their holdings of CELH. Vanguard Group Inc. lifted its position in Celsius by 183.6% in the fourth quarter. Vanguard Group Inc. now owns 13,746,472 shares of the company’s stock worth $749,458,000 after purchasing an additional 8,899,873 shares during the period. Wellington Management Group LLP lifted its position in Celsius by 212.2% in the fourth quarter. Wellington Management Group LLP now owns 3,393,586 shares of the company’s stock worth $185,018,000 after purchasing an additional 2,306,598 shares during the period. Eagle Asset Management Inc. lifted its position in Celsius by 188.8% in the fourth quarter. Eagle Asset Management Inc. now owns 2,958,771 shares of the company’s stock worth $161,312,000 after purchasing an additional 1,934,400 shares during the period. Price T Rowe Associates Inc. MD lifted its position in Celsius by 424.9% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 2,793,210 shares of the company’s stock worth $152,287,000 after purchasing an additional 2,261,046 shares during the period. Finally, Capital International Investors lifted its position in Celsius by 200.0% in the fourth quarter. Capital International Investors now owns 2,632,977 shares of the company’s stock worth $143,550,000 after purchasing an additional 1,755,318 shares during the period. Institutional investors and hedge funds own 60.95% of the company’s stock.

About Celsius

Celsius Holdings, Inc develops, processes, markets, distributes, and sells functional energy drinks and liquid supplements in the United States, Australia, New Zealand, Canadian, European, Middle Eastern, Asia-Pacific, and internationally. The company offers CELSIUS, a fitness drink or supplement designed to accelerate metabolism and burn body fat; various flavors and carbonated and non-carbonated functional energy drinks under the CELSIUS Originals and Vibe name, as well as functional energy drink under the CELSIUS Essentials and CELSIUS On-the-Go Powder names; and CELSIUS ready-to drink products.